SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ANNOUNCED THE SUSPENSION OF THE H SHARES OF ITS SUBSIDIARY SHANGHAI FUHUNG HANLIN BIOTECHNOLOGY CO., LTD. (“FUHONG HANLIN”) FROM 9 A.M. ON 23 MAY 2024 AT 9:00 A.M. ON MAY 23, 2024. This discontinuation is due to the publication of an announcement on related matters related to Resurrection Pharmaceuticals. The Executive Directors of Fuxing Pharmaceuticals include Mr. Wu Yifang, Mr. Wang Ke Chin, Ms. Guan Xiaofui and Mr. Wen De Yung; Non-Executive Directors are Mr. Chan Kai Yu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Tung Fai; the Independent Non-Executive Directors are Ms. Li Ling, Mr. Tang Guan Leung, Mr. Wang Guan Tei and Mr. Yu Zishan。

SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ANNOUNCED THE SUSPENSION OF THE H SHARES OF ITS SUBSIDIARY SHANGHAI FUHUNG HANLIN BIOTECHNOLOGY CO., LTD. (“FUHONG HANLIN”) FROM 9 A.M. ON 23 MAY 2024 AT 9:00 A.M. ON MAY 23, 2024. This discontinuation is due to the publication of an announcement on related matters related to Resurrection Pharmaceuticals. The Executive Directors of Fuxing Pharmaceuticals include Mr. Wu Yifang, Mr. Wang Ke Chin, Ms. Guan Xiaofui and Mr. Wen De Yung; Non-Executive Directors are Mr. Chan Kai Yu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Tung Fai; the Independent Non-Executive Directors are Ms. Li Ling, Mr. Tang Guan Leung, Mr. Wang Guan Tei and Mr. Yu Zishan。